Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

The rising incidence and persistent dismal 5-year overall survival of pancreatic ductal
adenocarcinoma (PDAC) highlight the need for new effective systemic therapies …

Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …

Pancreatic adenocarcinoma (PAC) is associated with extremely poor prognosis and remains
a lethal malignancy. The main cure for PAC is surgical resection. Further treatment …

Importance New therapeutic options for patients with metastatic pancreatic ductal
adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination …

Nitric oxide and its production by iNOS is an established mechanism critical to tumor
promotion or suppression. Macrophages have important roles in immunity, development …

Here, we utilized spontaneous models of pancreatic and lung cancer to examine how
neoantigenicity shapes tumor immunity and progression. As expected, neoantigen …

The biological and functional heterogeneity between tumors—both across and within cancer
types—poses a challenge for immunotherapy. To understand the factors underlying tumor …

The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections
and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune …

The biology of solid tumors is strongly determined by the interactions of cancer cells with
their surrounding microenvironment. In this regard, pancreatic cancer (pancreatic ductal …